
(Accepted for publication February 23, 1998)

Specific Therapies of Biguanide-induced Lactic Acidosis

To the Editor.—Mercker et al.1 reported a case of severe biguanide-induced lactic acidosis. However, the authors did not discuss specific therapies. In such cases, the administration of sodium dichloracetate (DCA) should have been considered. DCA is an antidiabetic agent that activates the pyruvate dehydrogenase complex, the mitochondrial enzyme that catalyzes the conversion of pyruvate to acetylcoenzyme A and carbon dioxide. In dogs DCA has been reported to correct lactic acidosis induced by phenformin, another biguanide that induces lactic acidosis more commonly.2 In the patient described, an ongoing infection could have contributed to the overproduction of lactate. Even in endotoxin-induced lactic acidosis, DCA administration has been shown to reduce blood lactate levels.3,4 Administration of DCA could reduce plasma lactate levels in patients with lactic acidosis caused by various etiologies, even though in a large clinical trial, such intervention did not improve survival rates.5

Jean-Charles Preiser, M.D.
Jean-Louis Vincent, M.D., Ph.D.
Department of Intensive Care
Erasme University Hospital
Route de Lennik 808
B-1070 Brussels
Belgium

In Reply.—We appreciate the interest and comments of our colleagues regarding our case report and would like to thank the editorial board for the opportunity to respond. We agree with Lustik et al. that a patient’s diabetes mellitus should be under good control perioperatively. Therefore we would not stop metformin administration without starting an alternative therapy if appropriate. Nevertheless, we are much more concerned about perioperative metformin medication than Lustik et al. are. The patient mentioned in our case report was treated according to the recommendations suggested by Lustik et al. He presented no contraindications for metformin (except low caloric input) until he developed severe lactic acidosis. Therefore stopping metformin could prevent a rare, but significant, risk for the patient, whereas the potential benefits of continuing the drug are rather vague. According to the new manufacturer’s recommendations in Germany, metformin should be omitted 2 days before and after general anesthesia. The risk to develop perioperative problems that would

References


(Accepted for publication February 23, 1998)